Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab

NCT03286114 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Lack of patient population

Conditions

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia

Interventions

DRUG: Pembrolizumab

Sponsor

University of Michigan Rogel Cancer Center

Collaborators

[object Object]